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Abstract
Background: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western population.
Although genetic factors are considered to contribute to CLL etiology, at present genomic aberrations identified in
CLL are limited compared with those identified in other types of leukemia, which raises the question of the degree
of genetic influence on CLL. We performed a high-resolution genome scanning study to address this issue.
Findings: Using the restriction paired-end-based Ditag Genome Scanning technique, we analyzed three primary
CLL samples at a kilobase resolution, and further validated the results in eight primary CLL samples including the
two used for ditag collection. From 51,632 paired-end tags commonly detected in the three CLL samples
representing 5% of the HindIII restriction fragments in the genomes, we identified 230 paired-end tags that were
present in all three CLL genomes but not in multiple normal human genome reference sequences. Mapping the
full-length sequences of the fragments detected by these unmapped tags in seven additional CLL samples
confirmed that these are the genomic aberrations caused by small insertions and deletions, and base changes
spreading across coding and non-coding regions.
Conclusions: Our study identified hundreds of loci with insertion, deletion, base change, and restriction site
polymorphism present in both coding and non-coding regions in CLL genomes, indicating the wide presence of
small genomic aberrations in chronic lymphocytic leukemia. Our study supports the use of a whole genome
sequencing approach for comprehensively decoding the CLL genome for better understanding of the genetic
defects in CLL.
Findings
CLL (Chronic lymphocytic leukemia) is an incurable dis-
ease mainly affecting the B cell lineage in the western
population, with a median age of diagnosis of 72 year
old [1]. Determining the cause of CLL is crucial for
understanding the acquisition and for clinical diagnosis,
treatment and prognosis of CLL. Genetic factors have
been linked to the etiology of CLL. Cytogenetic analyses
identified chromosomal abnormalities including
del11q23 affecting the ATM gene, tri12, del 13q14, and
del17p13 affecting TP53 gene [2]. In addition, CGH
studies found gains and losses in Xp11.2-p21 and Xq21-
qter [3]. Molecular studies identified three genes: IgVH,
CD38 and ZAP-70 that correlate with CLL prognosis
[4-6]. A CLL-specific microRNA signature was also
identified, suggesting that microRNA deletion could be
involved in CLL [7]. SNP array studies identified 2q21.2,
6p22.1 and 18q21.1 abnormalities that follow a Mende-
lian inheritance pattern [8]. Whole genome association
studies also identified multiple loci at 2q37.3, 8q24.21,
15q21.3 and 16q24.1 that appear to be associated with
genetic susceptibility to CLL [9].
Although evidence supports the involvement of
genetic factors in CLL, the frequency of genomic aberra-
tions identified in CLL is relatively lower than those
observed in the leukemias affecting other types of hema-
topoietic lineages [10]. This information suggests that
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tions than other types of leukemia. Alternatively, more
genomic aberrations may exist in CLL but these could
mainly be small lesions in the CLL genome that are dif-
ficult to detect using conventional technologies due to
their limited resolution. With the rapid progress of gen-
ome sequencing technologies, enthusiasm is increasing
for pursuing comprehensive detection of genomic aber-
rations in cancer by sequencing cancer genomes. In the
case of CLL, a critical issue is to know the degree of
genomic aberrations in order to justify the use of whole
genome sequencing approach to analyze CLL genome.
We reasoned if we can scan certain CLL genomes at
sufficient high resolution and at reasonable genome cov-
erage, we should gain first-hand information to estimate
the degree of genomic aberrations in CLL.
We recently developed the DGS (Ditag Genome Scan-
ning) technique that uses next-generation DNA sequen-
cing technologies to collect paired-end sequences from
restriction DNA fragments across a genome [11]. Using
this technique, we analyzed CLL genomes. Nine samples
of peripheral blood from untreated CLL patients diag-
nosed in Northwestern University Lurie Cancer Center
and University of Chicago Medical Center were used in
this study, of which three were used for paired-end tag
collection, and eight including two used in paired-end
tag collection were used for full-length sequencing ana-
lysis (Additional file 1: Supplemental Table S1).
Informed consent was made by the patients, and the use
of clinical CLL samples was approved by the institu-
tional review board of University of Chicago and North-
western University following institutional guidelines.
The detailed experimental process followed the pub-
lished protocol [11] and outlined in Figure 1. Briefly,
mononuclear cells were isolated from each CLL periph-
eral blood or bone marrow sample by using NycoPrep™
A solution (Axis-Shield). Human genomic DNA was
extracted from mononuclear cells by using QIAamp
DNA Blood Kit (QIAGEN) following the manufacturer’s
protocol. To generate the DGS library, genomic DNA
was fractionated by HindIII restriction digestion. The
restriction fragments were dephosphorylated by CIP and
cloned into pDGS-HindIII vector that contains two
MmeI sites next to the HindIII cloning site. The geno-
mic library was digested by MmeI to release two tags
from the cloned DNA fragments. The tag-vector-tag
fragments were then gel-purified, and re-ligated to form
a ditag library. Ditags were released from the vectors by
HindIII digestion, gel-purified, and concatemerized by
using T4 DNA ligase (Promega). The concatemers at
200 to 500 bps were agarose-gel-purified and used for
ditag sequencing by using a 454 GS20 sequencer (454
Life Sciences). Ditags were extracted from the resulting
sequences based on the HindIII sites. Same ditags were
combined to generate a unique ditag with the corre-
sponding copy numbers.
To generate the reference ditag database, virtual Hin-
dIII restriction fragments were generated from known
human genomic sequences. Two 16-bp virtual tags were
extracted from the 5’ and the 3’ ends of each virtual
fragment, and connected to form a reference ditag
representing the virtual DNA fragment. The following
sequences were used to extract the reference ditags:
1. Human genome reference sequences (hg18): http://
hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/
2. Human dbSNP 126: ftp://ftp.ncbi.nih.gov/snp/
organisms/human_9606
3. Chimpanzee genome reference sequences (Pan-
Tro2): http://hgdownload.cse.ucsc.edu/goldenPath/pan-
Tro2/bigZips/
4. Human GM15510 fosmid paired-end sequences:
http://www.ncbi.nlm.nih.gov/Traces/trace.cgi?
&cmd=retrieve&val=CENTER_PROJECT%20%3D%20%
22G248%22&size=0&retrieve=Submit
5. Celera human genome sequences: http://www.ncbi.
nlm.nih.gov/genomeprj/1431
6. Venter genome sequences: ftp://ftp.ncbi.nih.gov/
pub/TraceDB/Personal_Genomics/Venter/
7. Watson genome sequences: ftp://ftp.ncbi.nih.gov/
pub/TraceDB/Personal_Genomics/Watson/
8. Reference ditags were also extracted from HindIII
fragments of E.coli K12 genome sequences to eliminate
the ditags from E. coli DNA contaminated during library
construction process.
Initial ditag mapping was performed with perfect
match between experimental ditags and hg18 reference
ditags. For the unmapped experimental ditags, a single-
base mismatch in each single tag of the ditag was
allowed to compensate for possible sequencing error or
SNP. To identify the unmapped ditags related with
homopolymer generated by 454 sequencing chemistry,
the unmapped ditags with more than two homo-bases
were stretched, e.g. AAA -> AAAA, or shortened, e.g.
AAA -> AA, and mapped to reference ditags again. For
the ditags remaining unmapped, they were mapped to
the reference ditags of other sequence sources in the
ditag reference database. The ditags remaining
unmapped after these processes were defined as the
unmapped ditags.
Unmapped ditag sequences were used to design sense
primers and antisense (reverse/complementary) primers,
with four extra bases CAGC added to the 5’ end of
sense primer and CGCC to the 5’ end of antisense pri-
mer. Genomic DNA digested by HindIII was used as the
templates for PCR amplification. PCR was performed
with 35 cycles at 95°C 30 sec, 57°C 60 sec, and 72°C 3
min, followed by extension at 72°C for 10 min. The
amplified products in each reaction were cloned into
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Figure 1 Outline of the experimental process. Genomic DNA samples were digested by restriction enzymes. Ditags (paired-end tags) were
collected from both ends of restriction fragments and sequenced. The ditag sequences were compared to known human reference genome
sequences. The unmapped ditags were used as sense and antisense PCR primers to amplify their original DNA fragments to generate full-length
sequences. The sequences were mapped to reference genome sequences to determine the type of genomic aberrations.
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Page 3 of 12pGEM-T vector (Promega), transformed into E. coli
TOP10 (Invitrogen), and plated in a single well of the
48-well Qtrays (Genetix). Four clones from each trans-
formation were amplified by colony-PCR using M13F
and M13R primers, and sequenced by Big-Dye Termina-
tor v3.1 Cycle Sequencing Kit (ABI) using M13F primer.
For the sequences that did not reach the full-length, sec-
ond sequencing reactions were performed using M13R
primer. To determine the genomic aberrations, each
full-length sequence was mapped to hg18 using BLAT
at a minimum of 90% identity as the cut-off.
The paired-end ditags were collected from three CLL
samples. Genomic DNA from each sample was fractio-
nated by HindIII digestion, which provides 3,561-bp
resolution on average across the genome based on hg18
sequences [11]. Unique paired-end ditags of 272,193,
320,283, and 307,547 was collected from each CLL sam-
ple, covering 32%, 34% and 38% HindIII fragments in
each CLL genome respectively. Comparing the three
ditag sets shows that between 87,968 and 108,579 ditags
are present between two CLL samples, and 51,632 ditags
are commonly present in all three CLL samples (Table
1A). The ditags present only in individual CLL sample
could be the ditags representing individual genomic dif-
ferences, the ditags potentially originating from experi-
mental artifacts, or ditags detected in one but not in
others due to unsaturated ditag collection in each CLL
under the sequencing scale. The 51,632 ditags detected
in all three CLL samples cover 5% of genomic DNA
fragments commonly detected in the three CLL gen-
omes. In order to provide high confidence for further
downstream studies, we focused on the 51,632 common
ditags for further mapping analysis. We compared the
51,632 common ditags with multiple known human
genome sequences, including the human genome refer-
ence sequence hg18, human SNP, human GM15510
genome sequences, chimpanzee genome sequences that
are highly homologous to the humans, Watson genome
sequences, and Venter genome sequences. Of the 51,632
ditags used for the mapping, 98.3% (50,799) map to
hg18 that represent normal genomic fragments in the
CLL genomes, 0.4% (230) are unmapped ditags that
represent potential genomic aberrations commonly pre-
sent in all three CLL genomes, and the remaining ditags
map to other genomes that represent normal genome
variations (Table 1B).
To determine the types of genomic aberrations for the
unmapped ditags, we generated full-length sequence for
the restriction DNA fragment detected by the
unmapped ditags by using the “ditag-PCR” method, in
which the ditag sequences were used as PCR sense and
antisense primers to amplify the original DNA fragment
that derived the unmapped ditag. We performed 192
reactions in eight CLL samples including two used in
ditag collection and six additional CLL samples. Under
the conditions that a full-length sequence must be
longer than 50 bases and detected at least in the CLL
used in ditag collection or at least in two additional
CLL samples, 220 full-length sequences were generated
from 100 unmapped ditags. Mapping the full-length
sequences to hg18 identified different types of genomic
aberrations caused by insertion, deletion and base
change. Many of these aberrations created new HindIII
restriction site that leads to the release of unmapped
ditag, or the change of ditag sequence composition that
prevents ditag mapping. These aberrations were
observed in both coding and non-coding regions in CLL
genome. For example, aberrations were detected in
e x o n so fN E K 8 ,R U N X 1a n dM U C 2g e n e s ,a n di n t r o n s
of 20 other genes (Table 2A, Additional file 2: Supple-
mentary table S2). NEK8 encodes a member of the ser-
ine/threonine protein kinase family, which plays a role
in cell cycle progression from G2 to M phase and is
over-expressed in breast cancer [12]. A 353-base
sequence converted from the unmapped ditag AAGCT-
TACCCTCTGGACGCCTGTATGAAGCTT maps to
the last exon (Exon 15) coding for the 3’ UTR of NEK8.
Two HindIII restriction sites were inserted in the
sequence that are not present in the wild-type NEK8
g e n e .R U N X 1i sag e n ei n v o l v e di nA M Lt h r o u g hi t s
involvement in the t(8;21) [13]. A 434-base full-length
Table 1 Paired-end tags collected from three CLL samples
A. Ditag distribution in three CLL samples
CLL sample (%)
12 3
Total sequence reads 231,941 321,290 268,124
Total ditags 623,539 859,836 700,991
Unique ditag 272,188 (100) 320,278 (100) 307,542 (100)
Ditags common in two 99,815 99,815
87,968 87,968
108,579 108,579
Ditags common in three 51,632 (19) 51,632 (16) 51,632 (17)
B. Mapping ditags to reference human genome sequences
Mapped (%) Unmapped (%)
Total common ditags 51,632 (100)
HG18 50,799 (98.3) 833 (1.7)
Homopolymer 22 816
Chimpanzee genome 195 616
Other human Genomes 386* 230
GM15510 genome 28
Celera genome 165
Venter genome 352
Watson genome 61
Total unmapped 230 (0.4)
*These mapped to multiple genomes was counted only once.
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Page 4 of 12Table 2 Aberrations in exon and intron, and only present in CLL
Ditag Full-
length
(bp)*
CLL Sample** Chr. Location Aberration Gene
12345678 Exon Intron
A. Aberrations affecting exon and intron
AAGCTTACCCTCTGGACGCCTGTATGAAGCTT 353 + - - - - - - - 17q11.2 24093147-
24093483
Insertion NEK8
268 + + - - - - - - 19p13.2 10331021-
10331266
Insertion TYK2
AAGCTTCGGCCTATAGACAACCTAACAAGCTT 434 + + +++++-21q22.12 35949034-
35949460
Base change RUNX1
AAGCTTCCGGTCGGCTTCGCAGTAGAAAGCTT 410 - + - + - - - - 11p15.5 1084558-
1084956
Insertion MUC2 MUC2
AAGCTTGAGGGTGGAGTTCCTTCTGTAAGCTT 181 - + + - - - - - 2p11.2 87573183-
87573358
Base change,
insertion
BC070201
AAGCTTGGCCAGAGACAGGCATCATGAAGCTT 116 + - - - - - - - 10q22.1 73213666-
73213767
Base change CDH23
AAGCTTGTGGACCACCGCTGTGAGTCAAGCTT 300 + + + + + - + + 20p12.3 6033711-
6034006
Base change FERMT1
AAGCTTCATATGAGGATCAAAAACGAAAGCTT 283 + + - + + + - - 3p14.2 61015245-
61015527
Base change FHIT
AAGCTTCTTTGTGATGCTCAGACATGAAGCTT 332 - + - - - + - - 11q23.3 120263755-
120264067
Base change GRIK4
AAGCTTAGATCAGTGAGCCTACGGCGAAGCTT 605 + + ++++-+ 16q22.2 69601759-
69602345
Base change HYDIN
AAGCTTCGCCGTGGGCTCACTGATCTAAGCTT 614 + + + - + + + + 16q22.2 69601760-
69602350
Base change,
insertion
HYDIN
AAGCTTGCTGAACGCACCTGCGTGGAAAGCTT 448 + - + - - - + + 5q22.2 112671099-
112671541
Base change,
insertion
MCC
AAGCTTGCTTCTTTGCTGATACTGGCAAGCTT 582 - + + - - + - - 12q24.31 123563471-
123564048
Base change,
insertion
NCOR2
AAGCTTGGCGTCAATCCACACCAAAGAAGCTT 349 - - - - + + - - 5q33.1 149870225-
149870557
Insertion NDST1
1306 - - - + - + - - 8q22.2 99587880-
99589168
Base change,
insertion
STK3
AAGCTTGAAATAAGTGCTGCATCCTGAAGCTT 163 - + + - + - - - 2q32.1 182858618-
182858771
Base change,
insertion
PDE1A
AAGCTTTCCTAGGGAGCTGGGTGGTGAAGCTT 638 - - - + + - - - 17q25.1 68849242-
68849864
Insertion SDK2
211 + - - - - - - - 9q34.11 129692280-
129692481
Base change ST6GALNAC6
AAGCTTGCAGAAGGGGAGCCAGGGTGAAGCTT 312 - - + - - - + - 2p25.3 3382092-
3382390
Insertion TTC15
187 + - - - - + + - 13q12.13 26098258-
26098437
Base change,
insertion
WASF3
AAGCTTCAGGAAAGTCCACTAGCAAAAAGCTT 197 + + +++++- 9p13.3 33972115-
33972294
Insertion UBAP2
112 + - - - - - - - 9p13.3 33972115-
33972294
Insertion UBAP2
170 + - - - - - - - 9p13.3 33972115-
33972294
Insertion UBAP2
AAGCTTTAATGACTGAGGGGTTCTCAAAGCTT 1147 + + + - + - + - 6q25.3 157931989-
157933131
Base change ZDHHC14
AAGCTTTGAGAACCCCTCAGTCATTAAAGCTT 1134 + + - - - - + - 6q25.3 157931989-
157933131
Base change ZDHHC14
AAGCTTGCACAAGGGGCCCCTTGTGCAAGCTT 691 + - - - - - - - 4p16.3 2372796-
2373473
Insertion ZFYVE28
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Page 5 of 12sequence from a ditag AAGCTTCGGCCTATAG/
ACAACCTAACAAGCTT was detected in all eight CLL
samples, and maps to intron 3 and exon 4 of RUNX1.
Analyzing the mapped region shows a T to C single-
base change between the sequence and exon 4 of
RUNX1 gene. Searching dbSNP reveals that this is a
SNP (rs1235270). Due to the uncertainty of RUNX1
protein coding sequence itself, it is not certain if this
germline SNP causes a coding amino acid change. Sev-
eral bases are also changed in the mapped intron 3 of
RUNX1 gene. These base changes raise an interesting
question whether RUNX1 could be involved in CLL.
MUC2 is a member of the MUCIN family, which codes
for high molecular weight glycoproteins. The abnormal-
ities of MUC2 is linked with colorectal and pancreas
cancer [14]. A 410-base sequence derived from an
unmapped ditag AAGCTTCCGGTCGGCTTCGCAG-
TAGAAAGCTT covers intron 29, exon 30 and intron
30 of MUC2 gene. This sequence also contains two Hin-
dIII restriction sites AAGCTT inserted at both its ends
that do not exist in the wild-type MUC2 gene. Only
three aberrations were detected in the exon of three
known genes. This could be attributed to the limited
genome coverage of the study and the low percentage of
the exon-coding sequences in the genome. With
increased genome coverage, it would be possible to
identify the aberrations affecting more exons.
Aberrations also affect the introns of multiple genes.
FHIT encodes diadenosine 5’,5’’’-P1,P3-triphosphate
h y d r o l a s ei n v o l v e di np u r i n em e t a b o l i s m[ 1 5 ] .I ti s
located in the common fragile site FRA3B on chromo-
some 3, where carcinogen-induced damage can lead to
translocations in several cancers. A 283-base sequence
m a p st oi n t r o n8o fF H I Tg e n eb u ti t st a g1c o n t a i n s
GA to TG change. HYDIN encodes an axonemal pro-
tein; mutation of HYDIN is related to congenital hydro-
cephalus [16]. Two full-length sequences of 605-bp and
614-bp from two different unmapped ditags were
obtained from seven CLL samples. Both sequences map
to 21st intron of HYDIN. The 605-bp sequence contains
CCTACGGCG in its tag 2 converted from wild-type
gCcACaGCa (lowercase refers to the changed base), and
the 614-bp sequence contains CGCC converted from
wild-type tGCt in its tag 1 and an internal insertion.
NCOR2 is a transcriptional regulator that recruits his-
tone deacetylases to promoters [17]. A 582-base
sequence maps to intron 1 of NCOR2, but its tag 1 con-
tains an AAGC insertion, and tag 2 contains a C to T
change, an AG deletion, and a T insertion. TYK2 is a
member of the JAK family involving in IFN-g, IL-6,
IL-10 and IL-12 signaling. Mutation in this gene is asso-
ciated with hyperimmunoglobulin E syndrome [18].
A 268-base sequence maps to intron 14 of TYK2 but its
tag 1 contains an AAGCTTA insertion and its tag 2
contains a TGAAGCTT insertion. Both insertions create
HindIII restriction sites that lead to the generation of
the unmapped ditag. A 197-base sequence was detected
in seven CLL samples and two different sequences of
112-base and 170-base were generated from the CLL
used in ditag collection. All three sequences map to
UBAP2 located at 9p13.3, a gene involved in the ubiqui-
tination pathway [19]. For the 197-base sequence, its
178 bases map to intron 6 of UBAP2 gene and the
remaining 18 bases have no map, whereas the 112-base
and 170-base sequences contain different insertions.
Although the aberrations in many of these genes have
been correlated with different types of cancer, most
have not been linked with CLL.
Non-coding regions contribute to the majority of the
genome, and contain important functional elements
involving DNA replication, genome stability, regulation
of gene expression, and coding for non-coding tran-
scripts etc. Extensive characterization of non-coding
region could provide rich candidate markers for clinical
applications and identify the hotspots of genomic aberra-
tions involving cancer development. A total of 37
Table 2: Aberrations in exon and intron, and only present in CLL (Continued)
B. Sequences only present in CLL genome
AAGCTTGATATCGTGATCACCTTAAGAAGCTT 332 - + + - - - - - - - - - -
AAGCTTAGATAGAGCGCAGTCAACTGAAGCTT 107 + + ++++++ - - - - -
AAGCTTCCGGTCGGCTTCGCAGTAGAAAGCTT 159 + + + + - + - - - - - - -
AAGCTTCTCATCCTTCACCTTGGTCGAAGCTT 182*** + - - - - - - - - - - - -
540 - + - - - - + + - - - - -
3 6 2 ------+ + - - - - -
AAGCTTGAAAAAGGTTCAGGCAAACTAAGCTT 84 + - - - - - - - - - - - -
AAGCTTGCTGAACGCACCTGCGTGGAAAGCTT 923 - - + - - + - + - - - - -
AAGCTTGGCGTCAATCCACACCAAAGAAGCTT 347 - + + - - - - + - - - - -
AAGCTTTCTTGATAAGGCTCCTACGCAAGCTT 250 - + - - - - - + - - - - -
*A full-length sequence must be detected in at least one of the two CLL sampes used in ditag collection, or at least in one other CLL samples.
** Sample #1 and 2 were used for ditag collection.
***tag1 part map to chr1:56672307-56672331.
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Page 6 of 12Table 3 Aberrations in the intergenic region
Ditag FullL-length
(bp)
CLL sample chr. Location Aberration Nearby genes
1 2 3 4 5 6 7 8 Upstream Distance
(bp)
Downstream Distance
(bp)
AAGCTTACTTTCTCGGTTCCATTACTAAGCTT 614 - - + - - + + - 5q35.1 169443856-
169444467
Base change DOCK2 27,836 FOXI1 21,028
AAGCTTAGCCGGGCATCCTCTTTCCTAAGCTT 427 - -----+ +17q25.1 68688801-
68689216
Base change SSTR2 16,046 COG1 11,552
398 - + + - - - - - 15q26.1 88110782-
88111168
Insertion, base
change
MESP1 16,678 MESP2 9,425
AAGCTTAGTTTGGCTGCATGAGACTGAAGCTT 737 - - + - - - - + 16q23.1 74682385-
74683114
Base change
AAGCTTATGATGATCCCCTGAGCTAAAAGCTT 358 + ------- 1q23.3 162264795-
162265148
Insertion, base
change
2 6 4 +-------5p15.33 2449552-
2449774
Insertion
AAGCTTCAACGATAGTTCATCATCATAAGCTT 265 - + + - - - - - 16p13.3 808762-808956 Base change PRR25 4,900 LMF1 34,679
AAGCTTCAATAGCCGAAGCCAAACTAAAGCTT 556 + + - - + + + - 12q15 66234005-
66234554
Base change DYRK2 94,467
AAGCTTCACTCAGTCATATGGCATGGAAGCTT 130 - ----+ +-10q26.3 133154300-
133154419
Insertion
AAGCTTCACTGCAGCTATAACACTGCAAGCTT 920 + + + + + + - + 20p11.1 26157494-
26158252
Insertion, base
change
MIR663 20,580
AAGCTTCCTCTGTACTCACATTAACGAAGCTT 892 - + + - - + + - 9q12 67914079-
67914963
Base change
AAGCTTGAAATAAGTGCTGCATCCTGAAGCTT 606 + ------- 1q41 220652161-
220652760
Insertion, base
change
252 - - + - - - - + 20q13.13 46025615-
46025861
Base change
AAGCTTGACTCATTGCGTCTTATTCTAAGCTT 1060 + -------9q22.31 94477651-
94478404
Insertion IPPK 5,283 BICD2 35,062
AAGCTTGCACAAGGGGCCCCTTGTGCAAGCTT 606 + ------- 2q35 220216964-
220217558
Insertion SLC4A3 16,038
AAGCTTGCAGAAGGGGAGCCAGGGTGAAGCTT 553 - - - + - - - + 11q23.2 115071517-
115072057
Insertion
AAGCTTGCTGAACGCACCTGCGTGGAAAGCTT 758 - - - + + - - - 13q12.3 30403963-
30404714
Insertion, base
change
C13orf33 25,635 C13orf26 120
602 + + + - + - - + 1q42.13 227318140-
227318732
Insertion
AAGCTTGGAGCCCTAGCCACAATTGTAAGCTT 1453 - + - - + + + - 13q21.33 70285628-
70287080
Base change
AAGCTTGGCCAGAGACAGGCATCATGAAGCTT 900 + - + + - + - + 6q23.2 135162469-
135163363
Base change
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2Table 3: Aberrations in the intergenic region (Continued)
AAGCTTTCACTTCATTGGAGTCAGTGAAGCTT 322 + + + - + + + - 13q14.12 44367511-
44367832
Base change NUFIP1 43,552
AAGCTTTCCTAGGGAGCTGGGTGGTGAAGCTT 290 - - + - - - + - 2q21.2 132742087-
132742356
Insertion NCRNA00164MIR663B 10,075;
10,964
1 2 0 +-------4p15.33 14280120-
14280230
Insertion, base
change
AAGCTTTCCTTTTCCTTCTGCTCTTAAAGCTT 1071 + - + - - + - - 6q27 164534304-
164535365
Base change
AAGCTTTGCATTGGCAGAAGCCACCAAAGCTT 1039 - + - - - - + - 9q12 69920049-
69921093
Base change
AAGCTTTTAAGGGATCATGCCTCTCCAAGCTT 1534 + - + - + + + - 1q21.2 148015439-
148016961
Base change FCGR1A 3,951
AAGCTTACCCTCTGGACGCCTGTATGAAGCTT 185 + -------9q22.33 100893873-
100893975
Insertion TGFBR1 13,258
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Ditag Full-length (bp) CLL sample Chr. Location Sequence type
12345678
AAGCTTTCATTGGGATAACAGTGTTGAAGCTT 562 - + + - - + + + 2p11.1 132722630-132722850 ALR/Alpha
893 - + - - - - + - 2p11.1 91677156-91682632 ALR/Alpha
217 + + - + - - + - 2p11.1 91677835-91680254 ALR/Alpha
AAGCTTTCCAGTTAAGCTTTCTGGGGAAGCTT 1067 +++++++- 2p11.1 91257036-91258039
1002 + -----+-2p11.1 91257036-91258039
AAGCTTCTTTATGAGGAACAGTGTTGAAGCTT 216 ++++- -+- 2p11.1 91670531-91670746 ALR/Alpha
896 + + - + - - - - 2p11.1 91670531-91686712 ALR/Alpha
9 0 1 +-----+-2p11.1 91670531-91686712 ALR/Alpha
560 + - - - + - - - 2p11.1 91655191-91672448 ALR/Alpha
2231 ----+ +--2p11.1 91670550-91684334 ALR/Alpha
AAGCTTCTGAGAATGCCATCCCAATGAAGCTT 686 + -----+-2p11.1 91677155-91689898 ALR/Alpha
AAGCTTATTTGAGATGAAAGGAGTAGAAGCTT 1234 + + - - - - - - 2p11.1 91664565-91688410 ALR/Alpha
7 2 6 +++++++- 2p11.1 91676309-91680254 ALR/Alpha
AAGCTTCAACACTGTTGTTCCCAATGAAGCTT 612 - + + - - + - - 2p11.1 91676431-91689428 ALR/Alpha
AAGCTTCAATGGGATGAAGAGTGTTGAAGCTT 556 + + + - + + + - 2p11.1 91684461-91685014 ALR/Alpha
894 - - + - - - + - 2p11.1 91677156-91680254 ALR/Alpha
AAGCTTCAATTGGGATAACAGTGTTGAAGCTT 555 - - - + - + + + 2p11.1 91677836-91680592 ALR/Alpha
AAGCTTCATTAGGGATAACAGTGTTGAAGCTT 555 + + - - - + - - 2p11.1 91677156-91677709 ALR/Alpha
AAGCTTCATTGGGAACAACAGTGTTGAAGCTT 269 - + - - - - + - 2p11.1 91677155-91677709 ALR/Alpha
AAGCTTCATTGGGATGGCATTCTCAGAAGCTT 685 + -------2p11.1 91674610-91684466 ALR/Alpha
AAGCTTCTATTGGGATAACAGTGTTGAAGCTT 556 + + + - - + + + 2p11.1 91672232-91680592 ALR/Alpha
893 - + - - - - + + 2p11.1 91653836-91682632 ALR/Alpha
AAGCTTGACTCATTGCGTCTTATTCTAAGCTT 1179 - + + + + + + - 2p11.1 91031886-91033063 ERVL-B4-int
AAGCTTAAAACTCCTTTATGAAAAGAAAGCTT 637 + -------10q11.1 41848823-41861037 ALR/Alpha
AAGCTTAAACTCCGTGCATCAAAAGAAAGCTT 689 + + - - - - + - 10q11.1 41718813-41720661 ALR/Alpha
1407 + -------10q11.1 41718474-41727608 ALR/Alpha
6 0 1 +-------10q11.1 41718888-41720661 ALR/Alpha
AAGCTTAAACTTCTTGTATGAAAAGAAAGCTT 2067 - + + - - - + - 10q11.1 41847790-41864775 ALR/Alpha
1023 + + - - - - - - 10q11.1 41718797-41729299 ALR/Alpha
9 7 0 +-------10q11.1 41850170-41864775 ALR/Alpha
3 4 6 +-----+-10q11.1 41718460-41719477 ALR/Alpha
AAGCTTCAACGCTGCGCTATTGAAGGAAGCTT 345 - + + - - - - - 10q11.1 41726415-41729786 ALR/Alpha
8 6 0 ++++++++12p11.1 34724897-34729300 ALR/Alpha
AAGCTTCAACTCTGTCCGCCTAAAGGAAGCTT 175 ----+-+-10q11.1 41719301-41720316 ALR/Alpha
AAGCTTCAACTCTGTGCATTGGCCTCAAGCTT 279 ++++++++10q11.1 41849321-41850275 ALR/Alpha
6 2 2 ++++-++-10q11.1 41849321-41858079 ALR/Alpha
619 - + - - - + + - 10q11.1 41849321-41861137 ALR/Alpha
AAGCTTCAACTCTGTGCCGCTAAAGGAAGCTT 344 - + + - ++++10q11.1 41718623-41720492 ALR/Alpha
2280 + ----+--10q11.1 41717944-41720994 ALR/Alpha
1359 + -------10q11.1 41717944-41729975 ALR/Alpha
1190 + -------10q11.1 41718623-41720492 ALR/Alpha
6 8 1 +-------10q11.1 41720147-41729975 ALR/Alpha
AAGCTTCCTTCAGAAACAAGGAGTTTAAGCTT 858 + - + - + + + - 10q11.1 41718623-41720661 ALR/Alpha
AAGCTTCCTTTTAGGCCACAGAGTTGAAGCTT 348 - + + - - - - - 10q11.1 41719301-41720492 ALR/Alpha
1029 - + + - - - - - 10q11.1 41847960-41861361 ALR/Alpha
6 8 4 +-----+-10q11.1 41718622-41721845 ALR/Alpha
AAGCTTCCTTTTCATACAAGGAGTTTAAGCTT 1498 - + - - - + - - 10q11.1 41718461-41720661 ALR/Alpha
AAGCTTCTTTTTCATGCAAGGAGTTTAAGCTT 385 + - - - + + + - 10q11.1 41718767-41719477 ALR/Alpha
7 2 4 +-------10q11.1 41718767-41720661 ALR/Alpha
7 2 2 +-------10q11.1 41847452-41858698 ALR/Alpha
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Page 9 of 12sequences generated from 30 unmapped ditags mapped
to the non-coding regions in the genome with various
types of abnormalities (Table 3, Additional file 3: Supple-
mental Table S3). Although these loci are not directly
located in the coding regions, many genes are located
nearby the mapped locations. Of the 26 loci specifically
mapped by the sequences, 15 have genes located either
upstream, downstream or both within 100 kb distance.
For example, a 614 base sequence maps to 5q35.1
between169443856-169444467, where DOCK2 is located
27,836 base upstream and FOXI1 is located 21028 down-
stream. A 398-base sequence maps to 15q26.1 between
88110782 and 88111168, where two homologous tran-
scriptional factor genes, MESP1 and MESP2, are located
16,678-base upstream and 9,425-base downstream
correspondingly. microRNA gene MIR663 are located
20,580 base upstream of 20p11.1 between 26157494-
26158252 mapped by a 920-base sequence detected in
seven CLL samples. Another microRNA gene MIR663B
is located 10,964-base upstream of 2q21.2 between
132742087-132742356 mapped by a 290-base sequence,
of which a non-coding RNA gene NCRNA00164 is
located in between. The aberrations could affect the
nearby genes through influencing the regulation of gene
expression.
One hundred and forty seven full-length sequences
converted from 57 unmapped tags map to the highly
repetitive sequences in the non-coding regions. Of these
sequences, 110 sequences map to the ALR/Alpha satel-
lite sequences of the centromere, and chromosome 2,
Table 4: Aberrations in the centromere region (Continued)
AAGCTTTCCTTTAGGCCACAGAGTTGAAGCTT 1904 - + + - - - - - 10q11.1 41847960-41863582 ALR/Alpha
345 - - + + - - + - 10q11.1 41720491-41722352 ALR/Alpha
AAGCTTTCTTTTTCATCAAGGAGTTTAAGCTT 386 + -------10q11.1 41720293-41720661 ALR/Alpha
AAGCTTTGAAATCTCCCACCTAAAGGAAGCTT 408 + - + + + + + - 10q11.1 41718623-41722413 ALR/Alpha
750 - - + + - - - - 10q11.1 41847563-41863586 ALR/Alpha
1262 + -------10q11.1 41718623-41720552 ALR/Alpha
AAGCTTTTCTTTTCATCAAGGAGTTTAAGCTT 1379 - - + - - - + - 10q11.1 41718797-41720661 ALR/Alpha
691 - - + - - + - - 10q11.1 41718460-41720661 ALR/Alpha
2041 + -------10q11.1 41847790-41866145 ALR/Alpha
8 3 2 +-------10q11.1 41718460-41720661 ALR/Alpha
347 - - - + - + + - 10q11.1 41718460-41720661 ALR/Alpha
1024 + + - - - + + - 10q11.1 41718117-41720661 ALR/Alpha
AAGCTTTTGAGGCCAACACAGAGTTGAAGCTT 620 - + - - - + + + 10q11.1 41849321-41855026 ALR/Alpha
281 + + - - - - - - 10q11.1 41849321-41850276 ALR/Alpha
AAGCTTCCTGTGATGATTCGAGAGAGAAGCTT 1419 + + - - + + - - 17p11.1 22175465-22179262 ALR/Alpha
5 7 6 -----+ + + 17p11.1 22182601-22184019 ALR/Alpha
1966 + - + - - - - - 17p11.1 22175465-22186396 ALR/Alpha
2314 - - + - - + - - 17p11.1 22173089-22186396 ALR/Alpha
2 3 4 ++++-+-+17p11.1 22170709-22172128 ALR/Alpha
578 + + + - - + - + 17p11.1 22176307-22179262 ALR/Alpha
1090 - + - - - - + + 17p11.1 22170709-22179262 ALR/Alpha
AAGCTTTCTCTCTCGACATCACAGAGAAGCTT 641 + -------17p11.1 22178721-22179262 ALR/Alpha
1389 + -------17p11.1 22175464-22184019 ALR/Alpha
1824 + -------17p11.1 22175464-22181640 ALR/Alpha
579 - + - - + + + - 17p11.1 22170709-22179262 ALR/Alpha
1420 - + + - + + - - 17p11.1 22180222-22184019 ALR/Alpha
AAGCTTCTCTCTCGAACATCGCAGAGAAGCTT 1091 + ----+-+ 17p11.1 22173083-22184019 ALR/Alpha
749 - - + - - - - + 17p11.1 22183291-22184019 ALR/Alpha
AAGCTTCTCTGAGATGTTCGAGAGAGAAGCTT 579 ++++- -++17p11.1 22181236-22184019 ALR/Alpha
918 + + + - - - - - 17p11.1 22173087-22184019 ALR/Alpha
407 - + - + - + - - 17p11.1 22174101-22184019 ALR/Alpha
406 - - + - - - - + 17p11.1 22175464-22176883 ALR/Alpha
1087 + -------17p11.1 22175459-22181640 ALR/Alpha
AAGCTTCTGAGAATGCTTTTCTGAAAAAGCTT 355 + + - - + + + - 17p11.1 22184624-22184977 ALR/Alpha
1037 + -------17p11.1 22184624-22186848 ALR/Alpha
AAGCTTTGAGACCTGTCTCAGAGTTGAAGCTT 799 + + + - + + + - 17p11.1 21687309-21687527 ALR/Alpha
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Page 10 of 1210, and 17 are among the most frequent ones (Table 4,
Additional file 4: Supplemental Table S4): 23 sequences
converted from 13 unmapped tags map to the centro-
mere of chromosome 2 at 2p11.1, 41 sequences con-
verted from 16 ditags map to the centromere of
chromosome 10 at 10q11.1, and 22 sequences converted
from 6 unmapped ditags map to the centromere of
chromosome 17 at 17p11.1. The presence of highly fre-
quent aberrations in ALR/Alpha satellite sequences in
these three chromosomes suggests that these could be
the hot spot of genomic aberrations in CLL. Aberrations
in repetitive sequences have been shown to contribute
to cancer development [20]. However, it is difficult to
analyze the aberrations in these highly repetitive regions
using the hybridization-based approach due to the diffi-
culty to designing specific probes. Our results show that
restriction sequencing-based approach provides a useful
tool to study the aberrations in these regions.
Ten full-length sequences generated from eight
unmapped ditags did not map to known human genome
sequences (Table 2B. Additional file 5: Supplementary table
S5). For example, a 107-base full-length sequence converted
from an unmapped ditag AAGCTTAGATAGAGCG-
CAGTCAACTGAAGCTT was detected in all eight CLL
samples. However, it does not map to the reference genome
sequences. These sequences represent the DNA contents
present in CLL genomes but not in normal genomes.
Through high-resolution scanning of three CLL gen-
omes and verifying the results using full-length
sequences and additional CLL genomes, our study pro-
v i d e se v i d e n c es h o w i n gt h ew i d ep r e s e n c eo fg e n o m i c
aberrations in CLL, of which most are small lesions.
Studies with increased number of CLL samples and at
high genome coverage will be required to better under-
stand the genetic aberrations in CLL. Although the
study used multiple genomics databases to eliminate the
changes from normal genomic polymorphism, further
studies with normal DNA from the same patient will be
required to fully distinguish somatic mutations from
germline variations in CLL.
Additional material
Additional file 1: Supplementary table S1. CLL samples used for the
study.
Additional file 2: Supplementary table S2. Aberrations in exon and
intron.
Additional file 3: Supplementary table S3. Aberrations in the
intergenic region.
Additional file 4: Supplementary table S4. Aberrations in the
repetitive region.
Additional file 5: Supplementary table S5. Aberrations only present in
CLL genomes.
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